Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional disease progression in children with inherited peripheral neuropathies: A prospective cohort study.

Journal of neuromuscular diseases·2026
Same author

[Vaccination of immunocompromised individuals: Expert opinion - update 2026].

Wiener klinische Wochenschrift·2026
Same author

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same author

Integration of retinal layer thinning into NEDA-3 predicts disability progression in multiple sclerosis.

Journal of neurology·2026
Same author

Association of behavioral problems and health-related quality of life in children with epilepsy.

Epilepsy & behavior : E&B·2026
Same author

Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohort.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Related Experiment Video

Updated: May 14, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Natalizumab therapy for highly active pediatric multiple sclerosis.

Barbara Kornek1, Fahmy Aboul-Enein, Kevin Rostasy

  • 1Department ofNeurology, Medical University of Vienna, WaehringerGuertel 18-20, A-1090 Vienna, Austria. barbara.bajer-kornek@meduniwien.ac.at

JAMA Neurology
|February 20, 2013
PubMed
Summary

Natalizumab effectively reduced relapses and MRI lesions in pediatric multiple sclerosis (MS) patients with breakthrough disease. However, some patients developed antibodies or experienced disease activity after stopping natalizumab treatment.

More Related Videos

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

Related Experiment Videos

Last Updated: May 14, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

Area of Science:

  • Neurology
  • Immunology
  • Pediatrics

Background:

  • First-line therapies for pediatric multiple sclerosis (MS) frequently fail, necessitating effective second-line treatments.
  • Natalizumab, a monoclonal antibody targeting α4 integrin, is approved for adults with relapsing-remitting MS.

Purpose of the Study:

  • To evaluate the safety and efficacy of natalizumab as a second-line treatment for pediatric patients with MS.
  • To assess natalizumab's impact on clinical and magnetic resonance imaging (MRI) outcomes in pediatric MS.

Main Methods:

  • Retrospective study involving 20 pediatric MS patients treated with natalizumab (300 mg every 4 weeks) across 11 centers in Germany and Austria.
  • Data collected included annualized relapse rates, Expanded Disability Status Scale (EDSS) scores, MRI lesion counts, adverse events, and JC virus antibody status.

Main Results:

  • Natalizumab significantly reduced mean annualized relapse rates (3.7 to 0.4, P < .001) and new T2/FLAIR lesions (7.8 to 0.5 per year, P < .001).
  • Median EDSS scores decreased (2 to 1, P < .02). Two patients developed neutralizing antibodies, and 5 of 13 tested positive for JC virus antibodies.
  • Relapse activity occurred in 6 of 8 patients within 6 months of discontinuing natalizumab.

Conclusions:

  • Natalizumab demonstrates potential safety and efficacy in pediatric MS patients with breakthrough disease.
  • Monitoring for adverse events, neutralizing antibodies, and JC virus status is crucial during natalizumab therapy.